NCT04453436View on ClinicalTrials.gov

HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Active, not recruitingOBSERVATIONAL

Enrollment

2,500

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

October 31, 2025

Conditions

HIVDrugResistance

Interventions

DRUG

Tenofovir Disoproxil

Genotipic resistance test

Trial Locations (1)

04039-032

Laboratório de Retrovirologia, EP2, São Paulo

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Federal University of São Paulo

OTHER